Kathleen S Bingham1, Ellen M Whyte2, Barnett S Meyers3, Benoit H Mulsant4, Anthony J Rothschild5, Samprit Banerjee6, Alastair J Flint7. 1. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 2. Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA. 3. Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, Westchester Division, New York, NY. 4. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 5. University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA. 6. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, NY. 7. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University Health Network, Toronto, Ontario, Canada; Toronto General and Toronto Rehab Research Institutes, Toronto, Ontario, Canada. Electronic address: alastair.flint@uhn.ca.
Abstract
OBJECTIVE: To examine whether cerebrovascular risk, executive function, and processing speed are associated with acute treatment outcome of psychotic depression in older adults. METHODS: The authors analyzed data from 142 persons aged 60 years or older with major depression with psychotic features who participated in a 12-week randomized controlled trial (RCT) comparing olanzapine plus sertraline with olanzapine plus placebo. The independent variables were baseline cerebrovascular risk (Framingham Stroke Risk Score), baseline executive function (Stroop interference score and the initiation/perseveration subscale of the Mattis Dementia Rating Scale), and baseline processing speed (color and word reading components of the Stroop). The outcome variable was change in severity of depression, measured by the 17-item Hamilton Depression Rating Scale total score, during the course of the RCT. RESULTS:Greater baseline cerebrovascular risk was significantly associated with less improvement in depression severity over time, after controlling for pertinent covariates. Neither executive function nor processing speed predicted outcome. CONCLUSION: This study suggests an association of cerebrovascular risk, but not executive function or processing speed, with treatment outcome of major depression with psychotic features in older adults.
RCT Entities:
OBJECTIVE: To examine whether cerebrovascular risk, executive function, and processing speed are associated with acute treatment outcome of psychotic depression in older adults. METHODS: The authors analyzed data from 142 persons aged 60 years or older with major depression with psychotic features who participated in a 12-week randomized controlled trial (RCT) comparing olanzapine plus sertraline with olanzapine plus placebo. The independent variables were baseline cerebrovascular risk (Framingham Stroke Risk Score), baseline executive function (Stroop interference score and the initiation/perseveration subscale of the Mattis Dementia Rating Scale), and baseline processing speed (color and word reading components of the Stroop). The outcome variable was change in severity of depression, measured by the 17-item Hamilton Depression Rating Scale total score, during the course of the RCT. RESULTS: Greater baseline cerebrovascular risk was significantly associated with less improvement in depression severity over time, after controlling for pertinent covariates. Neither executive function nor processing speed predicted outcome. CONCLUSION: This study suggests an association of cerebrovascular risk, but not executive function or processing speed, with treatment outcome of major depression with psychotic features in older adults.
Authors: M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds Journal: Psychiatry Res Date: 1992-03 Impact factor: 3.222
Authors: A F Schatzberg; J A Posener; C DeBattista; B M Kalehzan; A J Rothschild; P K Shear Journal: Am J Psychiatry Date: 2000-07 Impact factor: 18.112
Authors: Maria A Oquendo; Enrique Baca-Garcia; Alexei Kartachov; Vadim Khait; Carl E Campbell; Monique Richards; Harold A Sackeim; Joan Prudic; J John Mann Journal: J Clin Psychiatry Date: 2003-07 Impact factor: 4.384
Authors: Meryl A Butters; Ellen M Whyte; Robert D Nebes; Amy E Begley; Mary Amanda Dew; Benoit H Mulsant; Michelle D Zmuda; Rishi Bhalla; Carolyn Cidis Meltzer; Bruce G Pollock; Charles F Reynolds; James T Becker Journal: Arch Gen Psychiatry Date: 2004-06
Authors: Tom Jeerakathil; Philip A Wolf; Alexa Beiser; Joseph Massaro; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli Journal: Stroke Date: 2004-06-24 Impact factor: 7.914
Authors: Mark D Miller; Eric J Lenze; Mary Amanda Dew; Ellen Whyte; Elizabeth Weber; Amy E Begley; Charles F Reynolds Journal: Am J Geriatr Psychiatry Date: 2002 Sep-Oct Impact factor: 4.105
Authors: Howard J Aizenstein; Andrius Baskys; Maura Boldrini; Meryl A Butters; Breno S Diniz; Manoj Kumar Jaiswal; Kurt A Jellinger; Lev S Kruglov; Ivan A Meshandin; Milija D Mijajlovic; Guenter Niklewski; Sarah Pospos; Keerthy Raju; Kneginja Richter; David C Steffens; Warren D Taylor; Oren Tene Journal: BMC Med Date: 2016-11-03 Impact factor: 8.775
Authors: Breno S Diniz; Benoit H Mulsant; Charles F Reynolds; Daniel M Blumberger; Jordan F Karp; Meryl A Butters; Ana Paula Mendes-Silva; Erica L Vieira; George Tseng; Eric J Lenze Journal: JAMA Netw Open Date: 2022-06-01